BioSpace News Archive

Everest Medicines announced that the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China has approved the investigational new drug application under Class One category for SPR206, a novel, intravenous next-generation polymyxin product candidate in development for the treatment of multi-drug resistant gram-negative bacterial infections.

AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, announced positive high-level results from the PROpel Phase III trial.

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced data presentation at the Infectious Disease Society of America IDWeek™ 2021, taking place virtually from September 29 – October 3, 2021.

Cara Therapeutics, Inc. announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 3.20 p.m. ET.

4D Molecular Therapeutics announced a late-breaking presentation of preliminary clinical data from the on-going 4D-125 Phase 1/2 trial in patients with X-Linked Retinitis Pigmentosa will be presented at the upcoming Annual Society of Retina Specialists Annual Meeting 2021 that will take place in San Antonio, TX on October 8-12, 2021.

Capricor Therapeutics, a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced positive final data from the HOPE-2 clinical trial using CAP-1002 to treat patients in advanced stages of Duchenne muscular dystrophy.

Dentsply Sirona , announced the official launch of its partnership with Smile Train, the world’s largest cleft-focused organization.

InMed Pharmaceuticals Inc. today reported financial results for the fiscal year ended June 30, 2021.

Join the Company on Wednesday October 27th at 8:30am ET to hear about its AI vision and how it can enhance its deep technology

PetVivo Holdings, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.